2 citations
,
July 2022 in “Stem cell research & therapy”
This study found that a large number of pelagehair follicle mesenchymal stem cells can be efficiently isolated using two-step Ficoll Density Gradient Sedimentation, promoting hair growth by secreting exosomes in mice.
This study reported that pelagehair follicle mesenchymal stem cells isolated from mice using Ficoll Density Gradient Sedimentation can be obtained in large numbers and may promote hair growth via exosome secretion.
81 citations
,
January 2003 in “The FASEB Journal”
This study found that follistatin and activin interactions are important for hair follicle development and cycling in mice, suggesting that they may regulate processes involving BMP-2 and its antagonist.
15 citations
,
February 1999 in “The anatomical record”
This study found that defective cross-linking in hair cuticles is observable in a minority of mouse hair mutants, suggesting different proteins are involved in cross-linking across cell types.
PP405 is discussed as a potential treatment for hair loss, with excitement about its promise but skepticism about its current effectiveness. Users mention combining it with treatments like minoxidil, finasteride, and microneedling, but emphasize it is not a cure.
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
Norwood 7 hair loss is often excluded from trials to ensure treatments appear more effective and to reduce costs. Some believe treatments effective for Norwood 5 could work on Norwood 7, but companies prioritize market readiness.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Got small bald patches they say are from stress? PP405 sprays could help bring them back to life.PP405 is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier; its registered Phase 2 trial (NCT06393452) tested it once daily in 78 adults with pattern hair loss, for safety and tolerability. It is not approved, not for sale, and has not been studied in alopecia areata or stress-related shedding.
Did you know PP405 peptides can help protect your follicles from DHT?PP405 is not a peptide and does not block DHT: it is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier, aimed at waking dormant follicles. Its registered Phase 2 trial (NCT06393452) measured safety and tolerability in 78 adults with pattern hair loss; it is not approved and not for sale.